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Abstract
Background: We examined if a purported anti-inflammatory supplement (AF) abrogated Western-diet (WD)-induced
liver pathology in rats. AF contained: 1) protein concentrates from bovine colostrum and avian egg yolk; 2) herbal
adaptogens and antioxidants; and 3) acetyl-L-carnitine.
Methods: Nine month-old male Brown Norway rats were allowed ad libitum access to WD for 41–43 days and
randomly assigned to WD+AF feeding twice daily for the last 31–33 days (n=8), or WD and water-placebo feeding
twice daily for the last 31–33 days (n=8). Rats fed a low-fat/low-sucrose diet (CTL, n= 6) for 41–43 days and
administered a water-placebo twice daily for the last 31–33 days were also studied. Twenty-four hours following
the last gavage-feed, liver samples were analyzed for: a) select mRNAs (via RT-PCR) as well as genome-wide mRNA
expression patterns (via RNA-seq); b) lipid deposition; and, c) protein carbonyl and total antioxidant capacity
(TAC). Serum was also examined for TAC, 8-isoprostane and clinical chemistry markers.
Results: WD + AF rats experienced a reduction in liver Tnf-α mRNA (-2.8-fold, p< 0.01). Serum and liver TAC was
lower in WD+ AF versus WD and CTL rats (p<0.05), likely due to exogenous antioxidant ingredients provided
through AF as evidenced by a tendency for mitochondrial SOD2 mRNA to increase in WD +AF versus CTL rats
(p= 0.07). Liver fat deposition nor liver protein carbonyl content differed between WD+AF versus WD rats,
although liver protein carbonyls tended to be lower in WD +AF versus CTL rats (p =0.08). RNA-seq revealed that
19 liver mRNAs differed between WD+AF versus WD when both groups were compared with CTL rats (+/- 1.5-fold,
p<0.01). Bioinformatics suggest that AF prevented WD-induced alterations in select genes related to the transport and
metabolism of carbohydrates in favor of select genes related to lipid transport and metabolism. Finally, serum clinical
safety markers and liver pathology (via lesion counting) suggests that chronic consumption of AF was well tolerated.
Conclusions: AF supplementation elicits select metabolic, anti-inflammatory, and anti-oxidant properties which was in
spite of WD feeding and persisted up to 24 hours after receiving a final dose.
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Non-alcoholic fatty liver disease, also referred to as non-
alcoholic steatohepatitis (NASH), is a condition whereby
there is an increased deposition of fat in the liver result-
ing in inflammation and liver damage [1,2]. NASH has
accompanied the escalating prevalence in obesity with
nearly 37% of the U.S. population reporting to have this
disease [3]. Causes of NASH include but are not limited
to poor dietary choices [4-6] and the lack of adequate daily
physical activity [7-9]. With regard to dietary causes of
NASH, rodent models have clearly demonstrated that di-
ets high in sugar and fat, which is typical of ‘Westernized’
diets (WD), are mechanistically linked to the development
of this condition [10-12].
Given that a critical feature of NASH includes an in-
crease in liver oxidative stress, antioxidant supplementa-
tion may be a viable strategy in slowing the progression
of this disease. Indeed, sparse evidence suggests that
antioxidant supplementation may be beneficial in the
treatment and progression of diet-induced fatty liver dis-
ease [13]. Likewise, antioxidants are known to protect
cellular structures against damage from free radicals and
reactive oxygen species of lipid peroxidation [14-16];
both of which are known to be elevated during NASH
[17]. Inflammation is another critical feature of NASH,
and pro-inflammatory cytokines have been found to be
highly expressed due to lipid peroxidation via oxidative
stress [15,18,19]; an effect which can lead to down-
stream inflammation and liver damage [20]. Hence,
along with reducing oxidative stress, a dietary strategy
to reduce liver inflammation that occurs during diet-
induced NASH is also warranted in order to reduce
disease progression.
The purpose of the current study was to determine if
WD-induced increases in markers of NASH develop-
ment were reduced in adult Brown Norway rats after
30 days of dietary supplementation with a purported
anti-inflammatory and antioxidant (AF) supplement.
Specific AF ingredients included the following: 1) bo-
vine colostrum and hen egg yolk extract; 2) herbal
adaptogens and antioxidants; and 3) acetyl-L-carnitine.
We hypothesized that AF supplementation would re-
duce WD-induced markers of NASH development in
light of the plethora of data suggesting that these ingre-
dients possess antioxidant and anti-inflammatory prop-
erties [16,21-29]. In order to holistically examine the
molecular effects that AF supplementation exhibited on
liver physiology in the presence of WD feeding, RNA
deep-sequencing (RNA-seq) and advanced bioinformat-
ics on liver samples were also performed. Likewise,
clinical chemistry serum markers were assessed in
order to examine clinical safety as well as other poten-
tial metabolic effects AF supplementation exhibited in
lieu of WD ad libitum feeding.
Methods
Animals and dietary feeding paradigm
All experimental protocols were approved by the University
of Missouri’s Animal Care and Use Committee. Sixteen
9-month-old male Brown Norway rats (Charles River
Laboratory, O’ Fallon, Missouri) were assigned to one
of the following two groups: 1) ad libitum WD+AF
feeding twice daily (n=8); or 2) ad libitum WD +
water-vehicle placebo feeding twice daily (n =8). In
addition, six rats were fed a 14% protein, low-fat/low
sugar diet (CTL) and were administered a water-vehicle
placebo over the feeding period in order to examine if
the feeding protocol elicited metabolic stress upon the
liver. Of note, rats were singly housed in standard rat
cages in temperature-controlled animal quarters (21°C)
with a 0700–1900 light: 1900–0700 dark cycle that was
maintained throughout the experimental period.
Rats were provided 41–43 days of ad libitum WD or
CTL feeding in total. During days 1–10, rats were pro-
vided their respective diets only as a run-in period. Dur-
ing the remaining 31–33 days afterward, AF rats were
gavage-fed one human equivalent dose (human dose:
1,410 mg/dose, human eq. rat dose: 52 mg; from
methods of Reagan-Shaw et al. [30]) of the supplement
(4Life Transfer Factor Renuvo™, 4Life Research, Sandy,
UT, USA) dissolved in 1 ml of tap water under light iso-
flurane anesthesia, twice per day. WD and CTL rats
were gavage-fed 1 ml of tap water under light isoflurane
anesthesia, twice per day. The active ingredients present
within the purported AF supplement included a propri-
etary blend of: 1) bovine colostrum and hen egg yolk ex-
tract; 2) herbal adaptogens and antioxidants [Rhaponticum
carthamoides (root) extract, Schisandra chinensis (fruit) ex-
tract, Withania somnifera (root) extract, Camellia sinensis
(leaf) extract, Curcuma longa (rhizome) extract, piperine,
resveratrol]; and 3) Acetyl-L-carnitine. As AF is a propri-
etary blend, we chose not to disclose explicit ingredient
doses. However, the manufacturer provided our laboratory
with a third-party laboratory certificate of analysis, which
confirmed the identity, composition, potency and purity of
the formulation. Specifically, product identity, heavy
metals and physical testing were performed by Bio
Medical Research (Sandy, UT), pesticide testing was
performed by Flora Research Laboratories (Grants Pass,
OR), and microbiological testing was performed by
Advanced Laboratories (Salt Lake City, UT).
WD (TD.88137; Harlan Laboratories) contained the
following macronutrient profile: 4.5 kcal/g, 15.2% pro-
tein (expressed as %kcal), 42.7% carbohydrate (expressed
as %kcal), 42.0% fat (expressed as %kcal). Of note, this
diet has been used in prior rodent studies to elicit
NASH [31,32]. CTL (LabDiet® Certified CR 14% protein
rodent diet) contained the following macronutrient pro-
file: 3.5 kcal/g, 16.1% protein (expressed as %kcal), 69.3%
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as %kcal). Additionally, WD contained a high amount of
sucrose (34% by weight), whereas CTL contained a low
amount of sucrose (1.2% by weight). Food intakes were
carefully measured weekly (i.e., monitoring cage bottoms
for morsels, etc.) and total caloric intakes were calcu-
lated for the duration of the study.
Sacrificial procedures
Rats were administered either AF or a water placebo up
to 24 hours prior to sacrifice. On the day of sacrifice,
animal cages were removed from the animal quarters be-
tween 0800–0900 and food was removed from each
cage. Sacrifices took place between 1400–1900 and rats
were sacrificed under CO2 gas in their home cages in
order to minimize stress. Whole blood was subsequently
removed via heart sticks using a 21-gauge needle and
syringe, placed in a serum separator tube, centrifuged at
3200 rev/min for 5 min, and serum was aliquoted into
multiple 1.7 ml microcentrifuge tubes for subsequent
biochemical assays. Four median lobe liver sections
(~50–100 mg) were subsequently removed using stand-
ard dissection techniques and were preserved in the
following manners for each of these respective assays:
1) frozen in Trizol for real-time polymerase chain reac-
tion (PCR) and RNA-seq analyses; 2) flash frozen in li-
quid nitrogen for Oil Red-O staining; 3) refrigerated in
10% phosphate buffered formalin for hematoxylin and
eosin (H&E) staining; 4) flash-frozen in liquid nitrogen for
protein carbonyl and total antioxidant capacity (TAC)
assessment.
Serum and liver biochemical assays
Serum samples were assayed for TAC and 8-isoprostane
via spectrophotometric methods (Cayman Chemical, Ann
Arbor, MI) according to manufacturer instructions, and
general clinical chemistry markers as previously de-
scribed [33].
Approximately 50 mg of frozen liver samples were ho-
mogenized in 50 mM phosphate buffer with 1 mM
EDTA. Total protein content was determined spectro-
photometrically using a BCA kit (Thermo Scientific,
Waltham, MA), and samples were assayed for TAC and
protein carbonyls according to manufacturer instructions
(Cayman Chemical, Ann Arbor, MI). Of note, respective
TAC and protein carbonyl values were corrected for total
protein loaded for each assay.
Liver real-time PCR methods
Liver samples preserved in Trizol were lysed using a
high-speed shaking apparatus (Tissuelyser LT; Qiagen,
Germantown, MD) with RNase-free stainless steel beads.
RNA was subsequently separated into phases using the
Trizol method according to manufacturer’s instructions
and isolated/DNase treated with columns (Macherey-
Nagel, Bethlehem, PA, USA) and 1 μg of RNA was re-
verse transcribed into cDNA for real time PCR analyses.
Real-time PCR was performed using SYBR-green-based
methods with gene-specific primers [superoxide dismut-
ase (SOD)1, SOD2, p47phox, p67phox, interleukin (Il)-6,
and tumor necrosis factor (Tnf)-α] designed using primer
designer software (Primer Premier, Premier Biosoft, Palo
Alto, CA). The forward and reverse primer sequences are
as follows: SOD1 FP (5′→3′): TGTGTCCATTGAAGA
TCGTGTGA, SOD1 RP (5′→3′): TCTTGTTTCTCGT
GGACCACC, SOD2 FP (5′→3′): TTAACGCGCAGAT
CATGCA, SOD2 RP (5′→3′): CCTCGGTGACGTTCA
GATTGT, p47phox FP (5′→3′): ACGCTCACCGAG
TACTTCAACA, p47phox RP (5′→3′): TCATCGGGC
CGCACTTT, p67phox FP (5′→3′): GCTTCGGAAC
ATGGTGTCTAAGA, p67phox RP (5′→3′): AGAGT
CAGGCAGTAGTTTTTCACTTG, Il-6 FP (5′→3′):
AGGGAGATCTTGGAAATGAGAAAA, Il-6 RP (5′→3′):
TCATCGCTGTTCATACAATCAGAA, Tnf-α FP (5′→
3′): CCCAGAAAAGCAAGCAACCA, Tnf-α RP (5′→3′):
CCTCGGGCCAGTGTATGAGA.
Liver histology
Liver Oil Red-O staining was performed for lipid count-
ing using standard histology techniques on frozen tissue.
H&E staining was performed for lesion counting using
standard histology techniques on formalin-fixed tissue.
Following each respective histological procedure, digital
images were acquired via light microscopy using an
Olympus BX60 photomicroscope at ×10 magnification
(Olympus, Melville, NY). Lipid droplet accumulation
was then quantified using an automated split color
channel function within ImageJ (NIH, Bethesda, MD),
and H&E liver lesions were counted and scored by a
certified pathologist (Dr. Dae Kim, College of Veterinary
Medicine, University of Missouri).
Liver RNA-seq methods
RNA isolation and cDNA preparation
Two micrograms of liver RNA were sent to the University
of Missouri’s DNA Core for RNA-seq procedures. Briefly,
high RNA integrity of each sample was confirmed using
the BioAnalyzer 2100 automated electrophoresis system
(Bio-Rad, Hercules, CA, USA) prior to cDNA library con-
struction. cDNA library preparation was subsequently per-
formed using the manufacturer’sp r o t o c o lw i t hr e a g e n t s
supplied in Illumina’s TruSeq RNA sample preparation kit
v2. Briefly, poly-A containing mRNA was purified from
2 μg of total RNA, RNA was fragmented, double-
stranded cDNA was generated from fragmented RNA
and the index containing sample identifier adapters
were ligated to the ends. The final construct of each
purified library was evaluated using the BioAnalyzer
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the Qubit fluorometer using the quant-iT HS dsDNA re-
agent kit (Invitrogen, Life Technologies, Grand Island,
NY), and diluted according to Illumina’s standard sequen-
cing protocol for sequencing on the HiSeq 2000.
Illumina sequencing of NAc cDNA and statistical analyses of
RNA-seq data
RNA-seq procedures occurred at the University of
Missouri DNA Core and are described in more detail
elsewhere [34]. Briefly, following cDNA library con-
struction, samples were loaded onto a flow cell where
clusters of each oligo were replicated. Following this
procedure, flow cells were placed in the sequencer and
fluorescently-labeled bases were attached to the comple-
mentary bases of each sequence. The Illumina Genome
Analyzer recorded 50 bp reads. Reads were trimmed to
ensure adaptor sequence removal and tiled to a custom
reference using NextGENe v1.92 (SoftGenetics, State
College, PA).
Statistics and bioinformatics for liver RNA-seq data
Differential gene expression patterns were analyzed for
annotated genes between the WD+AF, WD, and CTL
groups using reads per kilobase per million mapped reads
(RPKM) values. Differentially expressed liver mRNAs were
considered to be significant when WD+AF/CTL fold-
change values>±1.5 and an independent t-test p-value<
0.01, whereas the same gene was not differentially
expressed between WD/CTL (p>0.05). Of note, these
analyses thresholds are similar to other recent RNA-seq
publications, which have used a 1.5-to-2.0 fold-change
cut-off and similar p-value significant thresholds [35-37].
Genes that were found to be altered with AF supplemen-
tation were subsequently entered into Ingenuity Pathway
Analysis (Qiagen) to elucidate gene networks and/or bio-
logical functions within the liver that were altered with AF
supplementation.
Statistics for non-RNA-seq data
Unless otherwise stated, dependent variables are presented
as mean±standard error and between-group comparisons
for dependent variables were performed using one-way
ANOVAs. Significance was set at an alpha level of 0.05.
When significance was observed, Tukey post-hoc compa-
risons were performed in order to determine specific
between-group differences.
Results
Between-treatment phenotypes following the feeding
intervention
During the feeding intervention, WD+AF and WD con-
sumed significantly more kilocalories than CTL (p<0.05;
Figure 1A). Interestingly, pre- to post-intervention body
masses remained unaltered within the CTL and WD +
AF rats, whereas WD rats weighed more after the inter-
vention compared to their baseline body mass values
(p< 0.01, Figure 1B). However, post-intervention omen-
tal and perirenal fat pad masses were similar between
WD+AF and WD rats (Figure 1C) suggesting that the
prevention of body mass gain with AF supplementation
may have been due to alterations in hydration, losses in
other fat pad masses (i.e., subcutaneous), and/or losses
in other tissue mass (i.e., liver, visceral organ, muscle
mass, and/or other tissue masses). Hence, this finding
warrants further interrogation.
Contrary to our hypotheses, WD+AF rats did not re-
sult in a decreased deposition of liver lipid accumulation
(Figure 1D). Specifically, the only lesions that occurred
amongst all treatments were signs of lipidosis, and the
degree of lipidosis included the following (data not
graphed): 1) non-existent in CTL rats; 2) mild in WD +
AF rats (n =8); and 3) minimal (n =1), mild (n =6), and
moderate (n= 2) in WD rats. While trichromatic stain-
ing is the preferred method for liver fibrosis detection,
other literature has demonstrated that significant fibrosis
can be detected with H&E staining [38]. Nonetheless,
our pathologist did not detect appreciable liver fibrosis
formation within or between groups.
Representative images of Oil Red O and H&E liver
stains are presented in Figure 2.
Markers of antioxidant capacity and liver oxidative stress
following the feeding intervention
Following the feeding intervention, WD+AF rats pre-
sented lower levels of liver (Figure 3A) and serum TAC
(Figure 3B). However, there was a paradoxical tendency
for liver protein carbonyls to decrease in WD+ AF rats
compared to CTL rats (p=0.08, Figure 3C). Interes-
tingly, only 25% of WD+AF rats presented detectable
serum 8-isoprostane levels, whereas 50% of WD and
66% of CTL rats presented detectable levels of this
marker (no statistics run; Figure 3D).
Liver real-time PCR results
Following the feeding intervention, WD +AF rats tended
to show an increase SOD2 mRNA (Figure 4A). WD +
AF rats also tended to show an increase in liver p47phox
mRNA compared to WD rats (p= 0.06, Figure 4E), as
well as a tendency for Il-6 to increase compared to CTL
rats (p=0.08, Figure 4F). Interestingly, WD+ AF rats
experienced a decrease in liver Tnf-α mRNA compared
to WD and CTL (Figure 4C) rats.
Liver RNA-seq and bioinformatics suggests that AF may
shift liver away from carbohydrate metabolism
RNA-seq revealed that, out of 11,634 mRNAs that pos-
sessed RPKM values greater than 2.0, seven transcripts
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intake compared to CTL rats (A). WD rats experienced an increase in body mass pre- to post- intervention (B), although omental fat pad masses,
perirenal fat pad masses and liver fat deposition assessed during necropsies were not different between treatments (C/D). Abbreviations and
symbols: CTL=control low-fat/low-sugar 14% diet, WD=Western diet, WD+AF=Western diet+anti-inflammatory supplement; different superscript
letters represents differences between groups (p<0.05); In A, different superscript letters represents differences between groups (b>a, p<0.05); In B,
**represents a significant pre- to post-change in body mass within groups (p<0.01); In C, different superscript letters represents differences between
groups (for omental fat mass b>a, p<0.05; for perirenal fat mass d>c); In D, different superscript letters represents differences between groups
(b>a, p<0.05).
Figure 2 Representative Oil Red O and H&E photomicrographs. Images were captured using the 10× objective. Upper photomicrographs are
Oil Red O images whereby red-orange globules are lipid droplets. Lower photomicrographs are H&E images whereby cytosolic lipid vacuoles are
depicted by white arrows in the WD and WD+AF rats; note that all CTL rats presented minimal signs of these vacoules. White bars on H&E stains
represent 100 μm markers.
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scripts were down-regulated (fold-change -1.5, p< 0.01) in
WD+ AF versus WD rats when both groups were com-
pared to CTL rats (Table 1).
Bioinformatics suggested that the top biological func-
tion activated in WD+ AF versus WD rats included:
‘Increased Concentration of Lipid’ (Ahr, Cd36, Efna5,
Foxa2, Nr0b2, Pck1, Slc2a2 were up- or down-regulated
with WD+AF/CTL and did not change with WD/CTL;
categorical function p-value ranges=4.11E-8 to 2.32E-9).
The top associated liver gene network altered by WD+
AF but were not altered with WD when both condi-
tions were compared to CTL included: ‘Gene Expres-
sion, Carbohydrate Metabolism, Molecular Transport’
(score: 29; up-regulated mRNAs: Ltb, Nr0b2, Cd36,
Foxoa2, Hnf3; down-regulated mRNAs: Pepck, Pck1,
Slc2a2, Ahr, Ivns1abp) (Figure 5).
Serum clinical safety markers between groups following
the feeding intervention
Serum clinical safety markers following the intervention
are presented in Table 2. Serum glucose was signifi-
cantly lower in CTL compared to WD and WD +AF
rats (p<0.05). Serum alkaline phosphatase was significantly
lower in WD and WD+AF versus CTL rats (p<0.05).
Serum calcium was significantly lower in WD+AF and
CTL rats when compared to WD rats (p<0.05). Serum
creatinine was significantly lower in WD+AF and WD rats
when compared to CTL rats (p<0.05). There were no stati-
sitical differences in other clinical safety markers between
groups.
Discussion
Here we demonstrate that, in spite of of WD-induced
fatty liver development, AF supplementation: 1) reduces
Tnf-α mRNA; 2) tended to reduce liver protein carbonyl
levels and did decrease 8-isoprostane levels when these
animals were compared to CTL rats, albeit the latter
marker was also reduced in WD rats as well; 3) tended
to increase liver SOD2 mRNA, which encodes the mito-
chondrial superoxide dismutase antioxidant, when these
animals were compared to CTL rats; and 4) prevented
WD-induced alterations in select genes related to the
transport and metabolism of carbohydrates in favor of
select genes related to lipid transport and metabolism.
However, AF supplementation did not affect fatty liver
Figure 3 Markers of antioxidant capacity and oxidative stress following the feeding intervention. WD+ AF rats experienced a decrease in
liver (A) and serum total antioxidant capacity (B), although there was a paradoxical tendency for liver protein carbonyls to decrease in WD+AF
rats (C). Only 25% of WD+AF rats presented detectable levels of serum 8-isoprostane, a marker of systemic oxidative stress, whereas 50 and 66%
of the WD and CTL animals presented detectable levels of this marker (D). Abbreviations and symbols: CTL= control low-fat/low-sugar 14% diet,
WD=Western diet, WD+ AF=Western diet+anti-inflammatory supplement; In A/B, different superscript letters represents differences between
groups (a> b, p<0.05).
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serum clinical chemistry markers and liver histopath-
ology demonstrated that sub-chronic (30 days), twice
daily AF supplementation was well-tolerated, and that
the significant between-group effects were observed up
to 24 hours after receiving a final treatment dose. More
in depth discussion of these findings are presented
herein.
WD+AF rats experienced a significant reduction in
liver Tnf-α mRNA compared to WD and CTL rats. Chica-
nine, a major lignan present within Schisandra chinensis,
an active ingredient in AF, was recently reported by
Chen et al. [39] to significantly down-regulate LPS-
induced expression of Tnf-α m R N A ,a sw e l la so t h e r
pro-inflammatory cytokines in murine macrophages.
Similarly, Dushkin et al. [40] recently showed that eight
weeks of daily oral Rhaponticum carthamoides extract,
an active present in AF, significantly lowered serum
Tnf-α levels in high-fat diet fed six-month old male
Wistar rats. Green tea extract, another active ingredient
in AF, has been shown to protect against NASH in ob/
ob mice by decreasing the expression of adipose tissue
lipogenic genes, improving hepatic antioxidant defenses
and decreasing liver Tnf-α [21,22]. Likewise, Li et al.
[23] demonstrated that supplementing a high fat diet
with resveratrol, an active ingredient in AF, amerliorated
fibrosis, insulin resistance, glucose tolerance, dysregulated
lipid metabolism, oxidative stress, and pro-inflammatory
responses. Rivera et al. [24] similarly revealed that elevated
liver biomarkers of NASH were significanlty lower in
obese Zucker rats following 8-week treatment of resvera-
trol. The authors further explained that resveratrol was
able to increase adiponectin protein content and lower
Tnf-α protein content in the visceral adipose tissue of rats.
Therefore, a decrease in liver Tnf-α mRNA may have been
due to schisandra, rhaponticum, resveratrol, green tea ex-
tract, and/or other ingredients present in AF.
Serum and liver TAC were significantly lower in WD
+AF versus WD and CTL rats. We posit that the latter
findings could be a result of the exogenous antioxidant
ingredients being provided through AF which, in turn,
decreases the expression of total endogenous antioxidant
capacity across multiple tissues. In this regard, Valtuena
et al. [41] reported that diets high in total antioxidant
capacity significantly improved markers of inflammation,
but did not appreciably affect antioxidant status in
healthy adults. Foods high in antioxidants have also been
shown to prevent carotenoid secretion into circulation up
to 24 hours following feeding [42]. Likewise, while a con-
troversial topic [43], the possibility exists that exogenously
provided dietary antioxidants hamper endogenous antioxi-
dant systems [44]. However, the decrease in serum 8-
isoprostane levels in the WD+AF rats versus CTL rats
does provide a line of evidence suggesting that systemic
oxidative stress was still lower in the former group while
serum TAC was also reduced.
Figure 4 Effects of CTL, WD, and WD + AF feeding on SOD2 mRNA (A), SOD2 mRNA (B), Tnf-α mRNA (C), p47phox mRNA (D), p67phox
mRNA (E), and IL-6 mRNA (F). WD + AF rats experienced a decrease in liver Tnf-α mRNA expression (C) compared to WD and CTL rats; WD +
AF rats tended to increase liver SOD2 mRNA (A) and Il-6 mRNA compared to CTL (F) rats; WD + AF rats tended to increase liver p47phox mRNA
compared to WD (C) rats. Abbreviations and symbols: CTL = control low-fat/low-sugar 14% diet, WD = Western diet, WD + AF = Western diet +
anti-inflammatory supplement; In C, different superscript letters represents differences between groups (a > b, p < 0.05).
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Gene Gene function* WD+AF/CTL
Fold-change
WD/CTL
Fold-change
Efna5 Functions in pancreatic islet cells to regulate glucose-stimulated insulin secretion -2.20 -1.37
Ahr Mediates biochemical and toxic effects of halogenated aromatic hydrocarbons -1.93 -1.35
Pck1 Main control point for the regulation of gluconeogenesis -1.90 -1.31
Sall1 Transcriptional repressor involved in organogenesis -1.88 -1.41
Rasgef1b Guanine nucleotide exchange factor with specificity for Rap2a and other Ras family proteins -1.87 -1.35
Acadsb Member of the acyl-CoA dehydrogenase family of enzymes that catalyze the dehydrogenation of acyl-CoA
derivatives in the metabolism of fatty acids or branch chained amino acids.
-1.65 -1.31
Tmem56 Unknown function -1.62 -1.09
Ivns1abp Protects cells from cell death induced by actin destabilization -1.58 -1.08
Slc2a2 Mediates facilitated bidirectional glucose transport (a.k.a. Glut2) -1.56 -1.22
Hspa13 Members of this protein family play a role in the processing of cytosolic and secretory proteins, as well as
in the removal of denatured or incorrectly-folded proteins
-1.56 -1.11
Bach1 Plays important roles in coordinating transcription activation and repression by Mafk -1.52 -1.28
C21orf91 Unknown function -1.51 -1.16
Adcy9 Membrane bound enzyme that catalyses the formation of cyclic AMP from ATP 1.55 1.32
Cd36 Binds long chain fatty acids and may function in the transport and/or as a regulator of fatty acid transport 1.61 1.55
Slc39a4 Plays an important role in cellular zinc homeostasis as a zinc transporter 1.69 1.33
Foxa2 Encodes a member of the forkhead class of DNA-binding proteins, and can control the expression of liver-
specific genes such as albumin
1.69 1.29
Ces2 Participate in fatty acyl and cholesterol ester metabolism 1.73 1.41
Ltb Plays a specific role in immune response regulation 1.83 1.49
Nr0b2 Inhibits transcriptional activity of Neurod1 on E-box-containing promoter 2.99 2.39
Legend: bold-faced fold-change values indicate that genes that were altered by WD + AF but were not altered with WD when both conditions compared to
CTL rats. * = descriptions adapted from www.genecards.org.
Figure 5 Top IPA liver gene network altered in WD+AF versus WD rats compared to CTL rats. Notably, relative to WD/CTL comparisons,
WD+AF/CTL comparisons demonstrated a significant up-regulation in Cd36 (fatty acid transport) and down-regulation of Pck1 and Slc2a2 (both
of which are involved with gluconeogenesis and glucose transport, respectively). Left inset is a diagram of the top liver gene network significantly
altered (up- and down-regulated): ‘Gene Expression, Carbohydrate Metabolism, Molecular Transport’ (score: 29; up-regulated mRNAs: Ltb, Nr0b2, Cd36,
Foxoa2, Hnf3; down-regulated mRNAs: Pepck, Pck1, Slc2a2, Ahr, Ivns1abp). Right inset is the legend for transcript function, degree of up-regulation/
down-regulation, and interactive symbols.
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http://www.nutritionandmetabolism.com/content/11/1/19Liver protein carbonyl concentration within the mito-
chondria and nuclear compartments, but not within the
soluble cellular compartments such as the cytosol have
been linked to mammalian aging [44]; specifically, short-
lived animals were shown to possess higher concentra-
tions of liver protein carbonyls within the insoluble
cellular components such as the mitochondria, and
long-living animals were shown to possess reduced pro-
tein carbonyls within these cellular compartments. Inter-
estingly, within the present investigation, total liver
protein carbonyls tended to be lower in WD+ AF versus
CTL rats, which is suggestive of AF possessing poten-
tially anti-oxidant properties in the liver. Though AF
signficantly reduced serum and liver TAC, our study
findings would seem to suggest that AF possesses anti-
oxidant properties. This is of no surprise given that AF
contains green tea extract and resveratrol. Chung et al.
[22] reported that green tea extract inhibits ROS/RNS-
mediated damage while reducing serum alanine amino-
transferase (ALT) and decreasing lipid peroxidation and
protein nitration. Rubiolo et al. [25] similarly revealed
that resveratrol protects isolated primary rat hepatocytes
from necrosis induced by oxidative stress. Gómez-Zorita
et al. [27] demonstrated that a 6-week treatment of res-
veratrol significantly decreased lipid peroxidation, sug-
gesting a protective antioxidant effect against obesity
and steatosis-induced oxidative stress. It is noteworthy
to mention, however, that WD feeding in the current
study did not alter markers of oxidative stress when
comparing WD versus CTL rats. This finding was likely
due to the relatively sub-chronic WD feeding schedule.
However, NASH development appears to have been oc-
curring, as is evident from the observed liver fat depos-
ition, though no overt signs of oxidative stress became
apparent. Therefore, this finding suggests that, AF sup-
plementation reduces liver protein carbonyl formation
and may reduce systemic oxidative stress as evidenced
by only 25% of the animals presenting detectable levels
of serum 8-isoprostane compared to 50–66% of the rats
within the other groups presenting detectable levels of
this marker.
While liver TNF-α mRNA and oxidative stress markers
were favorably altered with AF supplementation, liver lipid
deposition remained unaltered. Pan et al. [45] reported
Table 2 Serum clinical safety markers between groups following the feeding intervention
Variable CTL (n= 6) WD (n= 8) WD+AF (n= 8) ANOVA p-value
Metabolic markers
Glucose (mg/dl) 143±11
a 205±13
b 204±13
b 0.005
Cholesterol (mg/dl) 74.7± 2.7 80.8± 2.0 77.8±2.2 0.21
Triglycerides (mg/dl) 73.3± 4.9 123.1±21.0 131.4±18.5 0.088
Markers of liver health and function
Total Protein (g/dl) 7.2±0.1 7.1±0.1 7.2± 0.2 0.81
Albumin (g/dl) 3.47± 0.03 3.36± 0.03 3.39±0.04 0.18
Total bilirubin (mg/dl) 0.10± 0.00 0.10± 0.00 0.10±0.00 1.00
Alkaline Phosphatase (U/L) 133±12
a 93±9
b 89±7
b 0.006
Alanine aminotransferase (U/L) 60.5± 11.3 75.3± 15.6 60.9±7.6 0.62
Gamma-glutamyltransferase (U/L) < 3 < 3 < 3 N/A
Globulin (g/dl) 3.70± 0.03 3.74± 0.03 3.78±0.08 0.67
Other serum markers
Sodium (mEq/L) 150±3 147±1 147±1 0.29
Potassium (mEq/L) 5.57± 0.21 5.60± 0.27 5.09±0.12 0.17
Chloride (mEq/L) 98.6± 1.5 99.6± 0.5 99.5±0.4 0.19
Total CO2 (mEq/L) 42.8± 1.0 40.9± 0.8 40.5±0.8 0.18
Calcium (g/dl) 11.1± 0.1
a 11.4± 0.1
b 11.2±0.1
a,b 0.043
Phosphorus (mg/dl) 6.12± 0.12 6.63± 0.19 6.21±0.06 0.038
Blood urea nitrogen (mg/dl) 16.0± 0.6 14.4± 0.5 14.3±0.6 0.082
Creatinine (mg/dl) 0.49± 0.01
a 0.45± 0.01
a,b 0.44±0.01
b 0.016
Creatine Kinase (U/L) 64.3± 5.4 69.8± 8.2 79.4±7.2 0.37
Notes: Tukey post-hoc comparisons performed when ANOVA p< 0.05; different letter superscripts indicate significant differences between groups.
“Legend: Bold-faced values are significant between-treatment differences when Tukey post-hoc comparisons performed (p < 0.05); different letter superscripts
indicate significant differences between groups.”
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http://www.nutritionandmetabolism.com/content/11/1/19similar findings when high-fat fed mice were provided ei-
ther a water- or ethanol-extracted schisandra fruit extract
for 13 days. Specifically, whereas hepatic steatosis was
ameliorated and liver injury reduced by the schisandra
treatment, significant increases in high and low density
lipoproteins occurred without any observable changes
occuring within measures of total cholesterol and triglyc-
erides. Jwa et al. [28], however, demonstrated that supple-
menting a high fat diet with piperine, another active
ingredient in AF, markedly decreased hepatic lipid despo-
sition in rodents. Nagao et al. [29] similarly reported that
dietary resveratrol has an anti-obesity effect in obese rats.
While it is difficult to reconcile our findings with the
aforementioned two investigations, this discrepancy may
be due to dosaging differences and/or the relatively short
length of the current study.
A unique aspect of this study was using RNA-seq as
an unbiased approach of examining liver transcriptome-
wide differences in WD+ AF versus WD animals when
both groups were compared to CTL rats. Bioinformatic
analyses suggest that AF potentially prevented WD-
induced alterations in select genes that lead to the trans-
port and metabolism of carbohydrates in favor of lipid
transport and metabolism. Interestingly, phosphoenol-
pyruvate carboxykinase (Pck1) was down-regulated with
AF supplementation. Gomez-Valades et al. [46] have
demonstrated that RNA interference against the Pck1
gene improves glycemic control, insulinemia and blood
lipid levels in db/db mice. Therefore, the AF-induced
downregulation of Pck1 may potentially lead to a longer-
term stability in liver carbohydrate and fatty acid metab-
olism in the midst of WD feeding. Glut2 (Slc2a2) was
also down-regulated with AF supplementation. Okamato
et al. [47] have illustrated in vitro that hepatocytes pre-
senting steatosis show an enhanced expression of Glut2
mRNA; this being an effect which the authors suggest
may be associated with liver gluconeogenesis and insulin
resistance. Therefore, while the WD-fed rats supple-
mented with or without AF presented high fasting glu-
cose levels suggestive of impaired glucose tolerance, the
AF-induced decrease in liver Glut2 mRNA may again be
potentially beneficial with regard to longer-term effects
on liver metabolism. This is in agreement with Dushkin
et al. [40] that reported an improvement in glucose sen-
sitivity and increased liver PPAR-α DNA-binding activity
in male rats treated with rhaponticum extract for eight
weeks. Cd36 was up-regulated with AF supplementation
and functions in the uptake of long chain fatty acids
along with oxidizing low-density lipoproteins. A plethora
of evidence suggests that a lowered Cd36 expression is
metabolically protective while overexpression is likely to
result in metabolic complications [47,48]. However, evi-
dence also exists suggesting that Cd36 may be integral
in glucose metabolism and insulin control [49-51].
Conclusions
In summary, these data suggest that AF elicits select
metabolic, anti-inflammatory, and anti-oxidant proper-
ties which were in spite of WD feeding. While others
have used similar animal numbers per experimental
treatment with transcriptome-wide interrogations [52]
and to study the effects of quercetin on liver physiology
in obese rats [53], a limitation of this study was that we
similarly used a relatively small number of animals per
experimental condition. Other potential limitations to
this study are that it was a sub-chronic feeding period
compared to other prolonged feeding protocols (i.e., 20+
weeks), and post-intervention tissue samples were col-
lected approximately 24 hours subsequent the final
treatment dosing. With regard to the former point, we
were able to observe markers indicative of the develop-
ment of fatty liver without advanced pathology in WD
and/or WD +AF rats (i.e., fibrotic lesion development).
Finally, we did not delve into specific mechanisms as to
how AF supplementation reduces liver TNF-α expres-
sion and protein carbonyl formation. Therefore, a more
mechanistic interrogation and studying the longer-term
effects of AF supplementation on liver physiology during
WD feeding are warranted. More specifically, because
the current findings as well as the aforementioned litera-
ture suggests that several ingredients within AF may be
efficacious in reducing liver fat deposition and metabolic
maladies that accompany a more prolonged WD feeding
schedule.
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